BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Moreno-Otero R, Trapero-Marugán M, Gómez-Domínguez E, García-Buey L, Moreno-Monteagudo J. Is interferon-beta an alternative treatment for chronic hepatitis C. World J Gastroenterol 2006; 12(17): 2730-2736 [PMID: 16718760 DOI: 10.3748/wjg.v12.i17.2730]
URL: https://www.wjgnet.com/1007-9327/full/v12/i17/2730.htm
Number Citing Articles
1
Roberto J. Firpi, David R. Nelson. Current and Future Hepatitis C TherapiesArchives of Medical Research 2007; 38(6): 678 doi: 10.1016/j.arcmed.2006.09.002
2
Kang Yiu Lai, Wing Yiu George Ng, Fan Fanny Cheng. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virusInfectious Diseases of Poverty 2014; 3(1) doi: 10.1186/2049-9957-3-43
3
Henry L. Y. Chan, Hong Ren, Wan C. Chow, Theodore Wee. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis CHepatology 2007; 46(2): 315 doi: 10.1002/hep.21683
4
Claude Souvignet, Olivier Lejeune, Christian Trepo. Interferon-based treatment of chronic hepatitis CBiochimie 2007; 89(6-7): 894 doi: 10.1016/j.biochi.2007.04.017
5
Carolina Scagnolari, Guido Antonelli. Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis CExpert Opinion on Biological Therapy 2013; 13(5): 693 doi: 10.1517/14712598.2013.764409
6
Keiji Matsui, Shogo Iwabuchi, Hirohito Shimizu, Atsushi Yoshida, Tomoaki Fujikawa, Kentaro Takatsuka. Two week induction of interferon‐beta followed by pegylated interferon alpha‐2b and ribavirin for chronic infection with hepatitis CHepatology Research 2010; 40(8): 757 doi: 10.1111/j.1872-034X.2010.00669.x